Loading…
Concord Biotech (CONCORDBIO)₹596.80−2.52%Pharmaceuticals
At the end of the Sep 2026 quarter, Concord Biotech's shareholders were: promoters 44.12%, FIIs 7.30%, DIIs 10.93%, public 37.65%. Promoter holding is up 0.01 percentage points from 44.11% a quarter earlier. FII holding is down 0.75 percentage points from 8.05% a year earlier. 0.00% of promoter shares were pledged. It had 88,330 shareholders.
As of · Company filings (shareholding pattern)
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 44.11% | 44.11% | 44.11% | 44.11% | 44.11% | 44.11% | 44.11% | 44.11% | 44.11% | 44.11% | 44.11% | 44.12% |
| FIIs | 7.02% | 6.51% | 7.13% | 8.12% | 8.35% | 9.37% | 9.12% | 8.05% | 7.60% | 7.81% | 7.55% | 7.30% |
| DIIs | 8.38% | 8.39% | 10.33% | 9.87% | 9.63% | 9.14% | 8.83% | 9.53% | 9.56% | 9.20% | 9.35% | 10.93% |
| Public | 40.49% | 40.99% | 38.43% | 37.90% | 37.91% | 37.38% | 37.94% | 38.31% | 38.73% | 38.88% | 38.99% | 37.65% |
| Promoter shares pledged | — | — | — | — | — | — | — | — | — | — | — | 0.00% |
| Number of shareholders | 87,451 | 83,263 | 80,705 | 84,264 | 81,971 | 81,187 | 82,012 | 82,617 | 81,782 | 82,216 | 83,292 | 88,330 |
| Holder | Category | Sep 2026 | Change (pp) |
|---|---|---|---|
| Sudhir Kumar Vaid | Promoter | 28.81% | 0.00 |
| Manju Vaid | Promoter | 9.59% | 0.00 |
| Aryaman Jhunjhunwala Discretionary Trust | Public | 8.04% | 0.00 |
| Nishtha Jhunjhunwala Discretionary Trust | Public | 8.00% | 0.00 |
| Aryavir Jhunjhunwala Discretionary Trust | Public | 7.98% | 0.00 |
| Sudman Consultants Llp | Promoter | 4.55% | 0.00 |
| Dsp Small Cap Fund | DII | 3.20% | +1.46 |
| Government Pension Fund Global | FII | 2.98% | 0.00 |
| Tata Aia Life Insurance Co Ltd Unit Linked Multi Cap Fund | DII | 2.69% | +0.20 |
| Axis Max Life Insurance Limited Ac Reversionary Bonus Participating Equity | DII | 1.34% | −0.01 |
| Ravindra Raichand Dharamshi | Public | 1.21% | 0.00 |
| Chanakya Corporate Services Pvt Ltd | Public | 1.12% | 0.00 |
| Sbi Healthcare Opportunities Fund | DII | 1.07% | New |
| Ankur Sudhir Vaid | Promoter | 0.56% | 0.00 |
| Vaid Megha Ankur | Promoter | 0.52% | 0.00 |
| Sonal Kumra | Promoter | 0.07% | 0.00 |
| Gaurav Kumra | Promoter | 0.01% | New |
| 1575773 Ontario Inc | Public | Exited | — |
| Ohm Stock Broker Private Limited | Public | Exited | — |
Promoters held 44.12% of Concord Biotech at the end of the Sep 2026 quarter, up 0.01 percentage points from 44.11% a year earlier.
In the Sep 2026 quarter, foreign institutional investors (FIIs) held 7.30% (down 0.25 percentage points from 7.55% a quarter earlier) and domestic institutions (DIIs) held 10.93% (up 1.58 percentage points from 9.35% a quarter earlier).
No. The Sep 2026 filing shows no pledged promoter shares.
Concord Biotech had 88,330 shareholders at the end of the Sep 2026 quarter, against 82,617 a year earlier.
Aryaman Jhunjhunwala Discretionary Trust (Public) held 8.04% at the end of the Sep 2026 quarter, the largest named holding outside the promoter group.